Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: J Antibiot (Tokyo). 2014 Oct 1;68(4):271–278. doi: 10.1038/ja.2014.133

Figure 4.

Figure 4

In vitro time-kill assessment of capuramycin (1), UT-01320 (3), and the first-line TB drugs (rifampicin and INH).

Log-kill reduction in log10 CFU/mL at the concentrations of the molecules at 2× and 4× MIC. A: 2× MIC of rifampicin (0.4 μg/mL), INH (0.2. μg/mL), UT-01320 (3.0 μg/mL), capuramycin (24.0 μg/mL).; B: 4× MIC of rifampicin (0.8 μg/mL), INH (0.4. μg/mL), UT-01320 (6.0 μg/mL), capuramycin (48.0 μg/mL).